Johnson Financial Group Inc. Has $8.94 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Johnson Financial Group Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,736 shares of the company's stock after selling 2,709 shares during the quarter. Johnson Financial Group Inc.'s holdings in Johnson & Johnson were worth $8,937,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Oregon Pacific Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth about $949,000. Horan Securities Inc. grew its holdings in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after purchasing an additional 90 shares during the period. Strategic Financial Concepts LLC grew its position in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after acquiring an additional 1,271 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $69,859,000. Finally, KPP Advisory Services LLC grew its holdings in Johnson & Johnson by 4.7% during the 4th quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock valued at $1,662,000 after purchasing an additional 515 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Leerink Partners cut their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $171.82.

Johnson & Johnson Stock Up 0.5 %

Shares of NYSE:JNJ traded up $0.78 during midday trading on Monday, hitting $155.36. 5,799,419 shares of the stock were exchanged, compared to its average volume of 7,920,029. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The business's fifty day simple moving average is $159.48 and its two-hundred day simple moving average is $154.80. The company has a market capitalization of $373.81 billion, a PE ratio of 23.36, a P/E/G ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.